Kök Hücre Nakli ve COVID-19 Pandemisi

Year 2022, Volume: 11 Issue: 1, 161 - 172, 29.04.2022

Yasemin Karacan , Rıdvan Ali

https://doi.org/10.47493/abantmedj.983037

Abstract

Malign ya da malign olmayan nedenlerle hematopoietik kök hücre nakli yapılan hastalar, bağışıklık sistemi baskılanmış bir grup olduğundan COVID-19 ile karşılaşmaları açısından potansiyel olarak riskli olarak kabul edilmektedir. Bu hasta grubunun immünsüpresyon ile viral replikasyonu kontrol etme kabiliyetinin azalması hastanın durumunu ağırlaştırıcı bir faktör ya da aynı zamanda enflamatuar fazı azalttığı için koruyucu bir faktör de olabileceği düşünülmektedir. Pandemi nedeniyle kök hücre nakli merkezleri COVID-19 önleme ve semptom yönetimi ile ilgili kılavuzları takip etmeleri gerekmektedir. Bu derleme, pandemi sürecinde hematopoietik kök hücre nakli hastalarının tedavi ve bakım sürecinin incelenmesi amacıyla hazırlanmıştır.

Keywords

COVID-19, Pandemi, Kök hücre nakli

Stem Cell Transplantation and COVID-19 Pandemic

Abstract

Patients undergoing hematopoietic stem cell transplantation for malignant or non-malignant reasons are considered to be potentially at risk for encountering COVID-19, as they are an immunocompromised group. The decrease in the ability of this patient group to control viral replication with immunosuppression is thought to be an aggravating factor or at the same time a protective factor as it reduces the inflammatory phase. Due to the pandemic, stem cell transplant centers are required to follow guidelines on COVID-19 prevention and symptom management. This review has been prepared to examine the treatment and care process of hematopoietic stem cell transplant patients during the pandemic period.

Keywords

COVID-19, Pandemic, Stem cell transplantation

References

• 1. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the progress and challenges of developing a vaccine for COVID-19. Frontiers in Immunology. 2020;11(October 2020):1–17.
• 2. Ciążynska M, Pabianek M, Szczepaniak K, Ułanska M, Skibinska M, Owczarek W, et al. Quality of life of cancer patients during coronavirus disease ( COVID-19 ) pandemic. Psycho-Oncology. 2020;(May):1–3.
• 3. EBMT V 15. Coronovirus Disease COVID-19 : EBMT. 2021. Available from: http://ovidsct/EBMT COVID-19 guidelines v. 15.02 2021-02.
• 4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA - Journal of the American Medical Association. 2020;323(20):2052–9.
• 5. Landman A, Feetham L, Stuckey D. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020;21(3):335–7. 6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;0(0):1–41.
• 7. WBMT. Origin of Global Data : Countries and participating institutions [Internet]. 4 Continental regions used for the WBMT Global Analysis. 2020 [cited 2021 May 16]. p. 13. Available from: https://www.wbmt.org/wp-content/uploads/2020/07/2016-survey-slides.
• 8. Xhaard A, Xhaard C, D’Aveni M, Salvator H, Chabi ML, Berceanu A, et al. Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: multicentre cohort study. British Journal of Haematology. 2021;192(5):e121–4.
• 9. Sağlık Bakanlığı. COVID-19 (SARS-CoV-2 Enfeksiyonu) Eri̇şki̇n hasta tedavi̇si̇. Vol. 19. 2021 [cited 2021 Jun 15]. p. 10,13. Available from: https://covid19.saglik.gov.tr.